VISTIN PHARMA ASA |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 23.5 NOK | -3.29% |
|
-1.67% | +0.86% |
| Apr. 24 | Transcript : Vistin Pharma ASA, Q1 2024 Earnings Call, Apr 24, 2024 | |
| Mar. 04 | Vistin Pharma ASA (OB:VISTN) acquired 15% stake in CF Pharma Ltd. for ?1.6 million. | CI |
| Sales 2021 | 279M 25.39M | Sales 2022 | 305M 27.78M | Capitalization | 701M 63.85M |
|---|---|---|---|---|---|
| Net income 2021 | 24M 2.19M | Net income 2022 | -4M -365K | EV / Sales 2021 | 2.96 x |
| Net cash position 2021 | 34.36M 3.13M | Net Debt 2022 | 47.73M 4.35M | EV / Sales 2022 | 2.45 x |
| P/E ratio 2021 |
34.6
x | P/E ratio 2022 |
-144
x | Employees | 78 |
| Yield 2021 |
3.87% | Yield 2022 |
4.75% | Free-Float | 45.24% |
More Fundamentals
* Assessed data
More news
Latest transcript on Vistin Pharma ASA
| 1 day | -3.29% | ||
| 1 week | -1.67% | ||
| Current month | +5.38% | ||
| 1 month | +6.33% | ||
| 3 months | +0.43% | ||
| Current year | +0.86% |
1 week
23.00
24.30
1 month
21.9024.30
Current year
21.6024.50
1 year
19.6025.10
3 years
11.2526.00
5 years
5.0029.45
10 years
5.0029.45
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | - | 20-02-29 | |
| Director of Finance/CFO | - | 20-03-01 | |
Eivind Egeli
CTO | Chief Tech/Sci/R&D Officer | - | 15-05-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Chairman | 76 | 20-05-31 | |
| Director/Board Member | 62 | 15-03-05 | |
| Director/Board Member | 60 | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-24 | 23.5 | -3.29% | 39,831 |
| 24-04-23 | 24.3 | +0.41% | 16,505 |
| 24-04-22 | 24.2 | +1.26% | 6,225 |
| 24-04-19 | 23.9 | -0.83% | 20,861 |
| 24-04-18 | 24.1 | +0.42% | 12,594 |
Real-time Oslo Bors, April 24, 2024 at 10:45 am EDT
More quotes
Vistin Pharma ASA is a Norway-based holding company, which operates through its subsidiary Vistin Pharma AS. The Company is engaged in the pharmaceuticals industry. The Company is a producer and supplier of Active Pharmaceutical Ingredients (APIs), which are used in medications for diabetes. Vistin Pharma offering such products: Metformin HCl (API); Metformin DC (direct compressible granules); Customized Particle Distribution (PSD) and Premix (Metformin + MgSt, can be delivered on-request). The Companyâs customers are pharmaceutical companies worldwide.
Sector
Pharmaceuticals
Calendar
2024-05-22
- Annual General Meeting
| 1st Jan change | Capi. | |
|---|---|---|
| +0.86% | 98.58M | |
| +17.97% | 42.77B | |
| +20.21% | 22.23B | |
| +13.12% | 14.44B | |
| +12.19% | 13.05B | |
| +35.45% | 11.59B | |
| -8.80% | 6.95B | |
| -0.05% | 6.79B | |
| -8.87% | 5.73B | |
| +6.29% | 4.97B |
- Stock Market
- Equities
- VISTN Stock
